Medicinal cosmetic lipoatrophy
Methods relating to local or “intralesional” injections of corticosteroids are provided. More specifically injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke to provoke cosmetic lipoatrophy of small fat deposits on the face and body.
1. A method of causing fat cell atrophy to decrease the size of a small fat deposit comprising the steps of:
identifying a small fat deposit of an individual to be decreased; and
administering, to the individual, an injectable composition comprising a corticosteroid, in the amount sufficient to cause a decrease in the size of the small fat deposit;
wherein the step of administering comprises injecting a sufficient amount of the composition, using a needle, into the small fat deposit of the individual, to cause a decrease in the size of the small fat deposit;
wherein the composition comprises between 1 to 9 mg of Triamcinolone acetonide as the corticosteroid in a physiologically and pharmaceutically acceptable vehicle; and
wherein the injectable composition comprises no vasoconstrictor agent.
2. The method of claim 1 wherein the injectable composition further comprises lidocaine.
3. The method of claim 1 wherein the injectable composition comprises the triamcinolone acetonide diluted in 0.5 to 5 ml of the physiologically and pharmaceutically acceptable vehicle having a concentration of lidocaine up to 2%.
4. The method of claim 3 wherein the injectable composition comprises the concentration of lidocaine of 0.02 g/ml.
5. The method of claim 1 wherein the step of administering the composition is performed by injecting the composition into the small fat deposit on the face or body of an individual.
6. The method of claim 1 wherein the step of administering the composition is performed after a step of removing a large fat deposit by liposuction.
7. The method of claim 1 wherein the administration step is repeated every month for three months.
8. The method of claim 1 wherein the size of the small fat deposit is between 10 cubic centimeters and 30 cubic centimeters.
9. The method of claim 1 wherein the step of administering the composition results in a localized concentration of the composition.
10. The method of claim 1 further comprising the step of:
determining a size of the small fat deposit;
determining a dose of corticosteroid in the composition required to reduce the size of the small fat deposit; and
administering a dose of corticosteroid of between 2 mg and 4 mg.
11. The method of claim 1 further comprising the step of
determining a size of the small fat deposit;
determining a dosage of corticosteroid required to reduce the size of the small fat deposit;
selecting the amount of the solution containing the corticosteroid; and
diluting the solution with the physiological acceptable medium to form the composition.
12. A method of causing fat cell atrophy to decrease the size of a small fat deposit comprising the steps of:
identifying a small fat deposit of an individual to be decreased; and
administering, to the individual, an amount of injectable components comprising a corticosteroid and a physiological acceptable medium, the amount sufficient to cause a decrease in the size of the small fat deposit;
wherein the step of administering comprises injecting a sufficient amount of the components, using at least one needle, into the small fat deposit of the individual;
wherein the administering step comprises more than one injection of the components at different locations of the small fat deposit;
wherein a composition of the components comprises between 1 mg to 9 mg of Triamcinolone acetonide as the corticosteroid in a saline or physiological pH solution as the physiological acceptable medium, the composition further comprising lidocaine.
13. The method of claim 12 wherein the composition comprises up to 2% of lidocaine.
14. The method of claim 12 wherein the composition comprises 2 mg of lidocaine.
15. The method of claim 12 wherein the components comprises the triamcinolone acetonide diluted in 0.5 to 5 ml of the saline or physiological pH solution having a concentration of lidocaine of 0.01 g/mL to 0.02 g/mL.
16. The method of claim 12 wherein the composition comprises a concentration of 2 mg/ml of triamcinolone acetonide.
17. The method of claim 12 wherein the composition comprises between 1 to 4 mg of triamcinolone acetonide.
18. The method of claim 12 wherein the composition comprises between 1 to 2 mg of triamcinolone acetonide.
19. The method of claim 12 wherein the composition comprises no vasoconstrictor agents.
20. The method of claim 12 wherein the size of the small fat deposit is between 10 cubic centimeters and 30 cubic centimeters.